Ariana Pelosci
Editor at Cancer Network
Assistant Managing Editor @cancernetwrk | University of Delaware ‘21 | Author of Roxy and Velvet’s Big Adventure
Articles
-
1 week ago |
targetedonc.com | Ariana Pelosci
A post hoc analysis of the phase 3b JUMP trial (NCT01493414), presented at the European Hematology Association 2025 Congress, indicates that adding erythropoiesis-stimulating agents (ESAs) or danazol to ruxolitinib therapy in patients with myelofibrosis and anemia does not compromise the efficacy of ruxolitinib in terms of spleen and symptom response rates.1 For patients with a hemoglobin (Hb) of less than 12.0 g/dL (n = 101), the spleen length response rate at 12 weeks was 41.6% and 36.6% at...
-
1 week ago |
targetedonc.com | Ariana Pelosci
New data from the phase 3 BM12 CAST trial (ACTRN12618000505202), presented at the European Hematology Association (EHA) 2025 Congress, indicates a significant advancement in graft-versus-host disease (GVHD) prophylaxis.
-
1 week ago |
cancernetwork.com | Ariana Pelosci
A combination of elranatamab-bcmm (Elrexfio), daratumumab (Darzalex), and lenalidomide (Revlimid) led to early and promising efficacy in patients with transplant-ineligible, newly diagnosed multiple myeloma, based on data from part 1, dose level G of the MagnetisMM-6 trial (NCT05623020) shared at the European Hematology Association 2025 Congress.
-
1 week ago |
curetoday.com | Ariana Pelosci
Among patients with EGFR-mutated non–small cell lung cancer (NSCLC), Rybrevant (amivantamab-vmjw) plus chemotherapy improved efficacy compared with chemotherapy alone according to results from the phase 3 MARIPOSA-2 trial assessing Tagrisso (osimertinib) resistance mechanisms, as presented at the 2025 American Society of Clinical Oncology Annual Meeting.
-
1 week ago |
onclive.com | Ariana Pelosci
Elranatamab-bcmm (Elrexfio) plus daratumumab (Darzalex) and lenalidomide (Revlimid) was safe and effective for patients with transplant-ineligible, newly diagnosed multiple myeloma, according to results from part 1, dose level G of the MagnetisMM-6 trial (NCT05623020) presented at the 2025 EHA Congress.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 42
- Tweets
- 91
- DMs Open
- No
RT @ginacolumbusonc: Great time in the Big Apple with some of our @OncLive and @CancerNetwrk crew at @gotoPER #NYGU today. Awesome work! 🙌🏻…
It was great speaking with Dr. Taplin today during #NYGU! Excited to see CancerNetwork’s Women in Oncology program come together.
It was a happy #InternationalWomensDay — we sat down with Dr Mary-Ellen Taplin of @DanaFarber to discuss her career in GU oncology! Keep your eye out for a brand new #womeninonc program 👀 #NYGU @gotoPER @APelosci #pcsm https://t.co/uvbciyxGiC
It was great speaking with Dr. Gong about the upcoming @myESMO meeting. He gave a great overview on upcoming presentations, and which will be most impactful in the bladder and gastrointestinal space.
Thank you @CancerNetwrk @APelosci! Always a pleasure catching up on latest GI/GU cancer breakthroughs especially with an exciting @myESMO 2023 fast approaching @CSCancerCenter @CedarsSinaiMed @CedarsSinai